UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

733-P: Initiation of iGlarLixi vs. Basal-Bolus Insulin (BB) in Adults with Type 2 Diabetes (T2D) Advancing from Basal Insulin (BI) Therapy: The SoliComplex Real-World Study

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

739-P: iGlarLixi vs. Premixed Insulin Initiation in Adults with Type 2 Diabetes (T2D) Advancing from Basal Insulin (BI) Therapy: SoliComplex Real-World Study

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

156-LB: Nursing Burden Administering/Monitoring Complex Insulin Regimens vs. Basal Insulin/GLP-1 RA Fixed-Ratio Combinations (FRCs) for People with Type 2 Diabetes (PWT2D) in Long-Term Care (LTC)

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

19-LB: Treatment Intensification and Risk of Cardiovascular Events in Insulin-Treated Patients with Type 2 Diabetes: A United Kingdom Retrospective Cohort Study

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

345-OR: A Retrospective U.S. Real-World Evidence Study on Glycemic Goal Achievement within 2 Years Post-Basal Insulin Initiation

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

EFFICACY AND SAFETY OF IGLARLIXI IN HISPANICS AND NON-HISPANIC WHITES WITH TYPE 2 DIABETES

Endocrine practice, 2019-11, Vol.25 (11), p.1091-1100

2019

Volltextzugriff (PDF)

Efficacy and safety of lixisenatide as add‐on therapy to basal insulin in older adults with type 2 diabetes in the GetGoal‐O Study

Journal of diabetes, 2019-12, Vol.11 (12), p.971-981

2019

Volltextzugriff (PDF)

Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial

Advances in therapy, 2019-09, Vol.36 (9), p.2310-2326

2019

Volltextzugriff (PDF)

A1C Target Attainment in Patients with T2D Receiving iGlarLixi Who Reach PPG and FPG Targets in the Lixilan-L Trial

Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)

2018

Volltextzugriff (PDF)

Relationship of Ethnicity to Clinical Outcomes in iGlarLixi-Treated Patients with Type 2 Diabetes

Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)

2018

Volltextzugriff (PDF)

Glycemic Target Attainment in Insulin-Naïve Patients with T2D Receiving iGlarLixi

Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)

2018

Volltextzugriff (PDF)

Letters

American pharmacy, 1994-08, Vol.34 (8), p.5-6

1994

Volltextzugriff (PDF)

Fixed‐ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß‐cell function in people with type 2 diabetes

Diabetes, obesity & metabolism, 2022-06, Vol.24 (6), p.1159-1165

2022

Volltextzugriff (PDF)

Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist

Journal of managed care & specialty pharmacy, 2022-09, Vol.28 (9), p.958-968

2022

Volltextzugriff (PDF)

iGlarLixi versus premixed insulin initiation in adults with type 2 diabetes advancing from basal insulin therapy: The SoliComplex real‐world study

Diabetes, obesity & metabolism, 2023-05, Vol.25 (5), p.1249-1260

2023

Volltextzugriff (PDF)

When basal insulin is not enough: A dose–response relationship between insulin glargine 100 units/mL and glycaemic control

Diabetes, obesity & metabolism, 2019-06, Vol.21 (6), p.1305-1310

2019

Volltextzugriff (PDF)

Advancing Type 2 Diabetes Therapy with iGlarLixi in Older People: Pooled Analysis of Four Randomized Controlled Trials

Metabolism, clinical and experimental, 2023-05, Vol.142, p.155429, Article 155429

2023

Volltextzugriff (PDF)

Advancing type 2 diabetes therapy with iGlarLixi in older people: Pooled analysis of four randomized controlled trials

Diabetes, obesity & metabolism, 2024-03, Vol.26 (3), p.851-859

2024

Volltextzugriff (PDF)

Low incidence of gastrointestinal adverse events over time with a fixed‐ratio combination of insulin glargine and lixisenatide versus lixisenatide alone

Diabetes, obesity & metabolism, 2018-11, Vol.20 (11), p.2690-2694

2018

Volltextzugriff (PDF)

Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study

Diabetes therapy, 2020-11, Vol.11 (11), p.2629-2645

2020

Volltextzugriff (PDF)

Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US

Diabetes therapy, 2022-09, Vol.13 (9), p.1659-1670

2022

Volltextzugriff (PDF)

When basal insulin is not enough: response to M Davidson

Diabetes, obesity & metabolism, 2020-04, Vol.22 (4), p.711-712

2020

Volltextzugriff (PDF)

Effect of delay in treatment intensification in people with type 2 diabetes and suboptimal glycaemia after basal insulin initiation: A real‐world observational study

Diabetes, obesity & metabolism, 2024-02, Vol.26 (2), p.512-523

2024

Volltextzugriff (PDF)

Efficacy of iGlarLixi, a fixed‐ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements

Diabetes, obesity & metabolism, 2018-11, Vol.20 (11), p.2680-2684

2018

Volltextzugriff (PDF)

Factors associated with therapeutic inertia in individuals with type 2 diabetes mellitus started on basal insulin

Diabetes research and clinical practice, 2023-09, Vol.203, p.110888-110888, Article 110888

2023

Volltextzugriff (PDF)

1 – 25 von 53

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(51)
Reviews
(2)

Sprache

Englisch
(52)
Niederländisch
(1)

Erscheinungsjahr

n.n

Thema

Diabetes
(28)
Endocrinology & Metabolism
(27)
Insulin
(27)
Life Sciences & Biomedicine
(27)
Science & Technology
(27)
Hypoglycemia
(16)
Type 2 Diabetes
(15)
Diabetes Mellitus
(14)
Humans
(14)
Diabetes Mellitus, Type 2 - Drug Therapy
(13)
Iglarlixi
(12)
Medicine
(11)
Medicine & Public Health
(11)
Cardiology
(10)
Endocrinology
(10)
Internal Medicine
(10)
Glucose
(9)
Clinical Trials
(8)
Hemoglobin
(8)
Insulin Glargine
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

733-P: Initiation of iGlarLixi vs. Basal-Bolus Insulin (BB) in Adults with Type 2 Diabetes (T2D) Advancing from Basal Insulin (BI) Therapy: The SoliComplex Real-World Study

739-P: iGlarLixi vs. Premixed Insulin Initiation in Adults with Type 2 Diabetes (T2D) Advancing from Basal Insulin (BI) Therapy: SoliComplex Real-World Study

156-LB: Nursing Burden Administering/Monitoring Complex Insulin Regimens vs. Basal Insulin/GLP-1 RA Fixed-Ratio Combinations (FRCs) for People with Type 2 Diabetes (PWT2D) in Long-Term Care (LTC)

19-LB: Treatment Intensification and Risk of Cardiovascular Events in Insulin-Treated Patients with Type 2 Diabetes: A United Kingdom Retrospective Cohort Study

345-OR: A Retrospective U.S. Real-World Evidence Study on Glycemic Goal Achievement within 2 Years Post-Basal Insulin Initiation

EFFICACY AND SAFETY OF IGLARLIXI IN HISPANICS AND NON-HISPANIC WHITES WITH TYPE 2 DIABETES

Efficacy and safety of lixisenatide as add‐on therapy to basal insulin in older adults with type 2 diabetes in the GetGoal‐O Study

Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial

A1C Target Attainment in Patients with T2D Receiving iGlarLixi Who Reach PPG and FPG Targets in the Lixilan-L Trial

Relationship of Ethnicity to Clinical Outcomes in iGlarLixi-Treated Patients with Type 2 Diabetes

Glycemic Target Attainment in Insulin-Naïve Patients with T2D Receiving iGlarLixi

Letters

Fixed‐ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß‐cell function in people with type 2 diabetes

Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist

iGlarLixi versus premixed insulin initiation in adults with type 2 diabetes advancing from basal insulin therapy: The SoliComplex real‐world study

When basal insulin is not enough: A dose–response relationship between insulin glargine 100 units/mL and glycaemic control

Advancing Type 2 Diabetes Therapy with iGlarLixi in Older People: Pooled Analysis of Four Randomized Controlled Trials

Advancing type 2 diabetes therapy with iGlarLixi in older people: Pooled analysis of four randomized controlled trials

Low incidence of gastrointestinal adverse events over time with a fixed‐ratio combination of insulin glargine and lixisenatide versus lixisenatide alone

Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study

Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US

When basal insulin is not enough: response to M Davidson

Effect of delay in treatment intensification in people with type 2 diabetes and suboptimal glycaemia after basal insulin initiation: A real‐world observational study

Efficacy of iGlarLixi, a fixed‐ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements

Factors associated with therapeutic inertia in individuals with type 2 diabetes mellitus started on basal insulin

Suchergebnisse filtern